High-dose chemotherapy for the treatment of breast cancer is an area of active research. However, almost 20 years after the first reports of the application of this form of therapy to breast cancer, the indications for treatment, the efficacy of this form of therapy compared with standard chemotherapy or to doseintensive scheduling of chemotherapy, and the patients to whom it should be offered, remain areas of intense debate and controversy. We offer a brief review on the questions that remain to be answered and an assessment of the current state of knowledge in the field.
AntmanK.: Dose-intensive therapy in breast cancer. In: High dose cancer chemotherapy: pharmacology, hematopoietins, stem cells, Armitage J.O., Antman K.A. (Eds.). Williams and Wilkins, Baltimore, 1992.
2.
AntmanK.GaleR.P.: Advanced breast cancer: high dose chemotherapy and bone marrow autotransplants. Ann. Intern. Med., 108: 570–574, 1988.
3.
AyashL.LynchJ.CruzJ.ReichE.EliasA.WheelerC.SchwartzG.MazanetR.TeplerI.WarrenD.: High-dose multimodalily therapy for locally unresectable or inflammatory (stage IIIB) breast cancer. Proc. Am. Soc. Clin. Oncol., 12: A158, 1993 (abstract).
4.
AyashL.J.WheelerC.FaircloughD.SchwartzG.ReichE.WarrenD.SchnippcrL.AntmanK.FreiE. Ill, Elias A.: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J. Clin. Oncol., 13:20432049, 1995.
5.
BezwodaW.R.SeymourL.DanseyR.D.: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J. Clin. Oncol., 13: 2483–2489, 1995.
6.
BonadonnaG.ValagussaP.: Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med., 304: 10–15, 1981.
7.
BonadonnaG.ValagussaP.RossiA.TanciniG.BrambillaC.ZambettiM.VeronesiU.: Ten year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res. Treat., 5: 95–115, 1985.
8.
BrounE.R.SridharaR.SledgeG.W.LoeschD.KneeboneP.H.HannaM.HromasR.CornettaK.EinhornL.H.: Tandem autotransplantation for the treatment of metastatic breast cancer. J. Clin. Oncol., 13: 2050–2055, 1995.
9.
BuzdarA.U.KauS.W.HortobagyiG.N.AmesF.C.HolmesF.A.FaschiniG.HugV.TheriaultR.L.McneeseM.D.SingletaryS.E.: Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer, 69:448452, 1992.
10.
CocconiG.AlgeriR.ContuA. Dalla Palma M., Di Blasio B., Di Costanzo F., FaillaG., FosserV., GebbiaV., MorettiG.: Randomized trial of conventional versus a more intensive sequential chemotherapy as adjuvant treatment for stage II breast carcinoma with greater than or equal to 10 involved, axillary nodes. Proc. Am. Soc. Clin. Oncol., 13: A49, 1994 (abstract).
11.
CrumpM.PrinceM.GossP.E.: Outcome of extensive evaluation of women with > 10 positive axillary lymph nodes prior to adjuvant therapy for breast cancer. Proc. Am. Soc. Clin. Oncol;, 14: A107, 1995 (abstract).
12.
De GraafH., WillemseP.H., De Vries E.G., SleijferD.T., MulderP.O., van der Graaf W.T., Smit Sibinga C. T, van der Plocg E., DolsmaW.V., MulderN.H: Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur. J. Cancer, 30A: 150–153, 1994 (abstract).
13.
De VriesE.G., RodenhuisS., SchoutenH.C., HupperetsP.S., BlijhamG.H., BontenbalM., RodenburgC.J., MulderN.H: Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Proc. Am. Soc. Clin. Oncol., 13: A151, 1994 (abstract).
14.
DunphyF.R.SpitzerG.BuzdarA.U.HortobagyiG.N.HorwitzL.J.YauJ.C.SpinoloJ.A.JagannathS.HolmesF.WallersteinR.O.BohannanP.A.DickeK.A.: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J. Clin. Oncol., 8: 1207–1216, 1990.
15.
DunphyF.R.SpitzerG.FornoffJ.E.YauJ.C.HuanS.D.DickeK.BuzdarA.U.HortobagyiG.N.: Factors predicting long-term survival for metastatic breast cancer patients with high-dose chemotherapy and bone marrow support. Cancer, 73: 2157–2167, 1994.
16.
ExtraJ.M.BourstynE.EspieM. De Rocquancourt A., MorvanF., MartyM.: Intensive induction chemotherapy followed by mastectomy in inflammatory breast cancer. Proc. Am. Soc. Clin. Oncol., 12: A233, 1993 (abstract).
17.
ForastiereA.A.HakesT.B.WittesJ.T.WittesR.E.: Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules. Am. J. Clin. Oncol., 5: 243–247, 1982.
18.
FreiE.IIIAntmanK.TeicherB.SchnipperL.: Bone marrow autotransplantation for solid tumors-prospects. J. Clin. Oncol., 7:515–526, 1989.
19.
GianniA.M.SienaS.BregniM. Di Nicola M., DoderoA. Zambetti M., OreficeS.B., LuiniA., GrecoM., ZucaliR., ValagussaP., BonadonnaG.: 5-year results of high-dose sequential adjuvant chemotherapy in breast cancer with ? 10 positive nodes. Proc. Am. Soc. Clin. Oncol., 14: A61, 1995 (abstract).
20.
GisselbrechtC.LepageE.EspieM.ExtraJ.M.AndolenkoP.GerotaI.MartyM.: Cyclophosphamide, total body irradiation with autologous bone marrow infusion as consolidation for inflammatory and metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 6: A255, 1987 (abstract).
21.
GradG.LaneN.ZimmermanT.BitranJ.MickR.WilliamsS.: High dose chemotherapy and autologous stem cell support in metastatic breast cancer: the University of Chicago experience. Proc. Am. Soc. Clin. Oncol., 13: A94, 1994 (abstract).
22.
HendersonI.C.HayesD.F.GelmanR.: Dose response in the treatment of breast cancer: a critical review. J. Clin. Oncol., 6: 1501–1515, 1988.
23.
HillnerB.E.SmithT.J.DeschC.E.: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA, 267: 2055–2067, 1992.
24.
HryniukW.: The impact of dose intensity on the design of clinical trials. Semin. Oncol., 14: 65–74, 1987.
25.
HryniukW.BushH.: The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2: 1281–1288, 1984.
26.
HryniukW.LevineM.N.: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol., 4: 1162–1170, 1986.
27.
IsraelL.BreauJ.L.MorereJ.F.: Two years of high dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. Cancer, 57: 24–28, 1986.
28.
JaiyesimiA.J.BuzdarA.U.HortobagyiG.; Inflammatory breast cancer: a review. J. Clin. Oncol., 10: 1014–1024, 1992.
29.
JonesR.B.ShpallE.J. Ross M. Bast R., AffrontiM., PetersW.P: AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer. Current results. Proc. Am. Soc. Clin. Oncol., 9: 30, 1990 (abstract).
30.
KennedyM.J.BeveridgeR.A.RowleyS.D.GordonG.B.AbeloffM.D.DavidsonN.E.: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose intense induction as initial therapy for metastatic breast cancer. J. Natl. Cancer Inst., 83: 920–926, 1991.
31.
NiedhartJ.A.: Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony stimulating factor (GM-CSF). Breast Cancer Res. Treat., 20: S15-23, 1991.
32.
NortonL.: Implications of kinetic heterogeneity in clinical oncology. Semin. Oncol., 12: 231–249, 1985.
33.
OvermoyerB.DannleyR.GoormasticM.AndresenS. Lichtin, BolwellB.: Consolidation for high risk breast cancer with high-dose chemotherapy and autologous bone marrow rescue: Proc. Am. Soc. Clin. Oncol., 13: A174, 1994 (abstract).
34.
PatroneF.BallestreroA.FerrandoF.BremaF.MoraglioL.ValbonesiM.BastaP. Ghio R. Gobbi M., SessaregoM.: Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J. Clin. Oncol., 13: 840–846, 1995.
35.
PetersW.P.: High dose chemotherapy and autologous bone marrow support for breast cancer. In: Important advances in oncology, De VitaV.T., HellmanS., RosenbergS.A (Eds.), pp. 135–150, Lippincott, Philadelphia, 1991.
36.
PetersW.P.JonesR.B.VredenburghJ.ShpallE.J.HusseinA.ElkordyM. Rubin P. Ross M., AffrontiM.L., MoorseS., BerryD.: A large prospective randomised trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete response after intensive doxorubicin based induction chemotherapy (AFM). Breast Cancer Res. Treat. (Suppl.), 37:35, 1995 (abstract).
37.
PetersW.P.RossM.VredenburghJ.J.HusseinA.RubinP.DukelowK.CavanaughC.BeauvaisR.KasprzakS.: The use of intensive autologous bone marrow transplantation for breast cancer. Semin. Oncol., 21(4 suppl 7): 25–31, 1994.
38.
PetersW.P.RossM.VredenburgJ.J.WuK.RosnerG.WinerE.MeisenbergB.HusseinA.: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol., 11: 1132–1143, 1993.
39.
PetersW.P.ShpallE.J.JonesR.B.OlsenG.A.BastR.C.GockermanJ.P.MooreJ.O.: High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol., 6: 1368–1376, 1988.
40.
PetersW.P.ShpallE.J.JonesR.B.RossM.: High-dose combination cyclophosphamide (CPA), cisplatin (cDDP), and carmustine (BCNU) with bone marrow support as initial treatment for metastatic breast cancer. Three to six year follow-up. Proc. Am. Soc. Clin. Oncol., 9:31, 1990 (abstract).
41.
RahmanZ.FryeD.BuzdarA.HortobagyiG.: A retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy (HDCT) on the outcome of patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol 14:A78, 1995 (abstract).
42.
RodenhuisS.: Dutch randomized studies of high-dose chemotherapy in the adjuvant treatment of high risk breast cancer. In: Changes in the treatment of breast cancer, pp. 75–78, Madrid, June 5–6, 1995.
43.
SomloG.DoroshowJ.H.FormanS.J.LeongL.A.MargolinK.A.MorganRJ.Jr., RaschkoJ.W., AhnC., NagasawaS.: High dose doxorubicin, etoposide and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. Cancer, 73: 1678–1685, 1994.
44.
SwenertonK.D.LeghaS.S.SmithTHortobagyiG.N.GchanE.A.GuttermanG.U.BlumcnscheinG.R.: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res., 39: 1552–1562, 1979.
45.
WilliamsS.F.MickR.DesserR.GolickJ.BeschornerJ.BitranJ.D.: High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J. Clin. Oncol 7–1824-1830, 1989.
